Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 2,073,310 shares, a growth of 64.5% from the November 30th total of 1,260,732 shares. Currently, 5.8% of the shares of the stock are sold short. Based on an average trading volume of 1,377,957 shares, the short-interest ratio is currently 1.5 days. Based on an average trading volume of 1,377,957 shares, the short-interest ratio is currently 1.5 days. Currently, 5.8% of the shares of the stock are sold short.

Gain Therapeutics Stock Performance

NASDAQ GANX traded down $0.12 during trading hours on Tuesday, hitting $3.04. 460,651 shares of the stock were exchanged, compared to its average volume of 601,559. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The company has a market cap of $116.88 million, a price-to-earnings ratio of -4.98 and a beta of 0.05. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $4.34. The stock has a 50-day moving average of $2.87 and a 200 day moving average of $2.14.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). As a group, equities research analysts forecast that Gain Therapeutics will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Gain Therapeutics in the third quarter worth $28,000. JPMorgan Chase & Co. acquired a new position in Gain Therapeutics in the 3rd quarter valued at about $47,000. Benedict Financial Advisors Inc. lifted its holdings in Gain Therapeutics by 55.6% in the 3rd quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock valued at $62,000 after purchasing an additional 12,500 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics during the 3rd quarter worth about $68,000. Finally, Virtu Financial LLC grew its holdings in shares of Gain Therapeutics by 126.9% during the third quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after buying an additional 30,207 shares in the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on GANX shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th. Maxim Group increased their price objective on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 22nd. Roth Capital restated a “buy” rating and issued a $10.00 price target on shares of Gain Therapeutics in a research report on Friday, December 19th. Finally, BTIG Research reiterated a “buy” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Gain Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.